王树文生物技术的PD-L1检测试剂盒验证了领导药物临床试验

王树文标志

患者具有更高的PD-L1表达先进食管鳞状细胞癌可以从主导PD-1抗体药物更好受益

德清,中国,2018年9月17日/美通社B3C / -亚博网网址王树文生物技术是中国第一推出本地制造专有PD-L1的测试试剂盒,其可准确地确定PD-L1的在肿瘤组织中的表达状态,并为抗PD-L1 / PD-1的药物开发提供实验室测试服务。

Recently, the investigation of the safety, efficacy and molecular marker efficacy of Hengrui Medicince’s anti-PD-1 drug, SHR1210, in the treatment of patients with advanced esophageal squamous cell carcinoma who failed conventional therapy was published in the March 2018 issue of Clinical Cancer Research, in which one of Shuwen Biotech’s PD-L1 detection kits was used and clinical results showed that patients positive for PD-L1 (PD-L1 expression ≥ 5%) have a higher objective response rate.

王树文生物技术的PD-L1包和测试服务已经被领先的制药公司为数十家临床试验的抗PD-1免疫疗法,有助于肿瘤免疫治疗药物的开发。王树文生物技术的CAP认证的竖纹Guanz诊断实验室也成功地通过了CAP的多站点,PD-L1测试多国能力测试。


关于王树文生物技术
王树文Biotech公司是一家中国诊断公司成立于创新,专利保护和国际合作作为发展的战略平台的原则。2011年以来,王树文在第一的一流的诊断技术和专利,涵盖一系列新的生物标志物的独家亚博直播苹果破解版授权的形式建立等等与众多优秀的学术和商业机构,如耶鲁大学,芝加哥大学,BioNTech,Sphingotec战略合作伙伴关系for companion diagnostics and other diagnostics in the fields of cancer, women’s health, critical care, and health screening and other fields. Shuwen has also developed innovative and quality companion diagnostics and provided central lab testing services to leading pharmaceutical developers. Shuwen houses an in-house development team, CAP-accredited central labs, and ISO13485-certified IVD manufacturing facilities, all in line with global standards in order to continue to deliver transformational products and services to its customers globally and open new possibilities in the advancement of health.


yabo30

瓦法Amirkia
此邮件地址受spam bots保护。您必须启用浏览它。

发贴者萨宾Duntze,B3C集团有限公司

饼干使我们更容易为您提供我们的服务。随着我们业务的使用您允许我们使用cookies。